Neurizon Therapeutics (ASX:NUZ) this week disclosed new preclinical data for its lead ALS candidate, NUZ-001, that the company will present at the BIO International Convention 2026.
The company said the findings add to a growing mechanistic picture in which NUZ-001 appears to engage multiple pathways that support neuronal protein homeostasis and stress response biology across complementary models.
The company reported three principal datasets. In motor neurons, NUZ-001 prevented the decline in STMN2, an axonal maintenance and regeneration factor that is disrupted when TDP-43 function is impaired. In human neurosphere models exposed to stress, NUZ-001 restored expression of multiple regulators involved in mitochondrial and lysosomal function, autophagy, mitophagy and broader cellular clearance systems. In zebrafish larval stress models, treatment with NUZ-001 similarly restored expression patterns across a panel of proteostasis regulatory candidates, demonstrating activity beyond in vitro systems and suggesting a reproducible stress-adaptive mechanism across model types.
Those mechanistic observations build on earlier work showing that NUZ-001 enhances autophagy and proteasomal clearance, reduces p62 and LC3 levels in human iPSC-derived neurons, and restores BDNF levels while protecting against stress-induced phenotypes in vivo.
Neurizon says the data support a model in which NUZ-001 acts on key proteostasis regulators with consequences for TDP-43-related neuronal dysfunction and the endogenous systems that govern protein clearance and neuronal resilience.
Interim Executive Chairman Sergio Duchini said, “These findings provide important additional validation of the biological activity of NUZ 001 and further strengthen the mechanistic framework supporting its ongoing clinical development. What is particularly encouraging is the consistency of the signal across multiple independent model systems, spanning cellular 2D and 3D human neural models and in vivo settings. Together, these data continue to build confidence that NUZ-001 is engaging pathways directly relevant to ALS biology, including TDP 43 dysfunction, proteostasis and neuronal resilience. As our Phase 2 3 HEALEY ALS Platform Trial progresses, we believe these findings further support NUZ 001's potential as a differentiated therapeutic approach for ALS.”
Neurizon also highlighted clinical progress. Early Australian Phase 1 and open-label extension studies involving 12 participants suggested that NUZ-001 was generally safe and well tolerated and generated exploratory signals that supported its selection for the HEALEY ALS Platform Trial. Pooled Phase 1 data showed a slower decline in function and respiratory measures versus matched historical controls, and a survival analysis reported by Neurizon showed a 71 per cent reduction in the risk of death versus matched PRO ACT controls.
